Payment overview · 2025
General Payments
$1,144.22
51 reported records · 17 companies
Healthcare provider profile · identity verified
Walter Daniel Zant, MD
Allopathic & Osteopathic Physicians|Family Medicine · MADISON, GA · NPI 1760471585
Verified facts
What the public records show
CMS Open Payments records show Walter Daniel Zant, MD received $1,144.22 in general payments during 2025 across 51 reported records.
ABBVIE INC. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 520 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $245.09 | 21.4% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $245.05 | 21.4% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $95.60 | 8.4% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $83.18 | 7.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.66 | 6.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.64 | 5.6% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $60.08 | 5.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.23 | 5.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.34 | 3.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.80 | 3.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.27 | 2.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.13 | 2.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.59 | 1.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.89 | 1.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.86 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.14 | 1.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.67 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,144.22 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $184.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $184.52 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $168.44 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $105.84 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $95.60 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $83.18 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.66 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.53 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.30 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.42 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.41 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 520 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 113 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 186 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 125 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 127 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 292 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 47 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 87 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
125 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
113 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
186 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
186 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
127 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
102 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
292 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
520 | 81 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2000 | 446 |
| Amlodipine Besylate | Amlodipine Besylate | 1338 | 288 |
| Omeprazole | Omeprazole | 1244 | 290 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1133 | 215 |
| Metoprolol Succinate | Metoprolol Succinate | 1015 | 219 |
| Lisinopril | Lisinopril | 977 | 220 |
| Furosemide | Furosemide | 963 | 150 |
| Pantoprazole Sodium | Pantoprazole Sodium | 889 | 181 |
| Gabapentin | Gabapentin | 871 | 184 |
| Losartan Potassium | Losartan Potassium | 818 | 179 |
| Metformin Hcl | Metformin Hcl | 680 | 164 |
| Sertraline Hcl | Sertraline Hcl | 642 | 137 |
| Hydrochlorothiazide | Hydrochlorothiazide | 611 | 140 |
| Potassium Chloride | Potassium Chloride | 610 | 115 |
| Tamsulosin Hcl | Tamsulosin Hcl | 610 | 138 |
| Tramadol Hcl | Tramadol Hcl | 607 | 138 |
| Simvastatin | Simvastatin | 545 | 130 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 544 | 127 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 527 | 154 |
| Famotidine | Famotidine | 523 | 86 |
| Eliquis | Apixaban | 520 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 519 | 107 |
| Trazodone Hcl | Trazodone Hcl | 483 | 101 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 474 | 120 |
| Meloxicam | Meloxicam | 465 | 131 |
| Azithromycin | Azithromycin | 461 | 348 |
| Fluticasone Propionate | Fluticasone Propionate | 446 | 156 |
| Pravastatin Sodium | Pravastatin Sodium | 422 | 89 |
| Lorazepam | Lorazepam | 408 | 72 |
| Montelukast Sodium | Montelukast Sodium | 408 | 95 |
| Alprazolam | Alprazolam | 377 | 67 |
| Quetiapine Fumarate | Quetiapine Fumarate | 357 | 50 |
| Glipizide Er | Glipizide | 350 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 342 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 341 | 72 |
| Fluoxetine Hcl | Fluoxetine Hcl | 330 | 58 |
| Allopurinol | Allopurinol | 323 | 68 |
| Methylprednisolone | Methylprednisolone | 321 | 243 |
| Zolpidem Tartrate | Zolpidem Tartrate | 312 | 53 |
| Carvedilol | Carvedilol | 309 | 66 |
| Ozempic | Semaglutide | 292 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 286 | 73 |
| Donepezil Hcl | Donepezil Hcl | 281 | 63 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 270 | 113 |
| Citalopram Hbr | Citalopram Hydrobromide | 247 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 244 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 240 | 44 |
| Bupropion Xl | Bupropion Hcl | 237 | 45 |
| Celecoxib | Celecoxib | 230 | 47 |
| Memantine Hcl | Memantine Hcl | 216 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 211 | 164 |
| Clonazepam | Clonazepam | 211 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 187 | 36 |
| Jardiance | Empagliflozin | 186 | 38 |
| Finasteride | Finasteride | 184 | 43 |
| Glipizide | Glipizide | 184 | 35 |
| Pregabalin | Pregabalin | 181 | 47 |
| Buspirone Hcl | Buspirone Hcl | 179 | 26 |
| Spironolactone | Spironolactone | 174 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 171 | 36 |
| Cefdinir | Cefdinir | 164 | 136 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 164 | 37 |
| Metformin Hcl Er | Metformin Hcl | 163 | 39 |
| Amoxicillin | Amoxicillin | 153 | 122 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 151 | 83 |
| Atenolol | Atenolol | 150 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 149 | 37 |
| Mirtazapine | Mirtazapine | 148 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 147 | 27 |
| Fluconazole | Fluconazole | 145 | 85 |
| Estradiol | Estradiol | 144 | 40 |
| Xarelto | Rivaroxaban | 142 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 136 | 106 |
| Lovastatin | Lovastatin | 136 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 133 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 132 | 79 |
| Mounjaro | Tirzepatide | 127 | 23 |
| Linzess | Linaclotide | 125 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 24 |
| Ezetimibe | Ezetimibe | 122 | 27 |
| Meclizine Hcl | Meclizine Hcl | 120 | 46 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 116 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 116 | 99 |
| Farxiga | Dapagliflozin Propanediol | 113 | 24 |
| Nortriptyline Hcl | Nortriptyline Hcl | 113 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 112 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 112 | 93 |
| Temazepam | Temazepam | 111 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 31 |
| Prednisone | Prednisone | 109 | 52 |
| Ropinirole Hcl | Ropinirole Hcl | 109 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 108 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 108 | 29 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 107 | 26 |
| Alendronate Sodium | Alendronate Sodium | 102 | 27 |
| Trulicity | Dulaglutide | 102 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 100 | 20 |
| Ibuprofen | Ibuprofen | 98 | 36 |
| Cephalexin | Cephalexin | 97 | 84 |
| Ondansetron Hcl | Ondansetron Hcl | 97 | 44 |
| Risperidone | Risperidone | 95 | 14 |
| Nystatin | Nystatin | 94 | 56 |
| Januvia | Sitagliptin Phosphate | 93 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 93 | 20 |
| Clonidine Hcl | Clonidine Hcl | 92 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 13 |
| Olanzapine | Olanzapine | 89 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 89 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 88 | 16 |
| Trintellix | Vortioxetine Hydrobromide | 87 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 86 | 18 |
| Torsemide | Torsemide | 83 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 82 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 78 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 78 | 17 |
| Ondansetron Odt | Ondansetron | 78 | 35 |
| Synthroid | Levothyroxine Sodium | 78 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 17 |
| Glimepiride | Glimepiride | 74 | 11 |
| Gemtesa | Vibegron | 73 | 13 |
| Albuterol Sulfate | Albuterol Sulfate | 72 | 20 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 72 | 13 |
| Fenofibrate | Fenofibrate | 70 | 14 |
| Myrbetriq | Mirabegron | 69 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 68 | 56 |
| Divalproex Sodium | Divalproex Sodium | 67 | 11 |
| Sucralfate | Sucralfate | 67 | 18 |
| Valsartan | Valsartan | 67 | 15 |
| Risperdal Consta | Risperidone Microspheres | 66 | suppressed |
| Colchicine | Colchicine | 65 | 23 |
| Mupirocin | Mupirocin | 65 | 43 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 64 | 18 |
| Baclofen | Baclofen | 63 | 12 |
| Ranolazine Er | Ranolazine | 63 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 61 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 60 | 12 |
| Valacyclovir | Valacyclovir Hcl | 59 | 35 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | suppressed |
| Novolog Flexpen | Insulin Aspart | 56 | 14 |
| Benazepril Hcl | Benazepril Hcl | 55 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 55 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 12 |
| Levetiracetam | Levetiracetam | 54 | 13 |
| Verapamil Er | Verapamil Hcl | 51 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 50 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 49 | 17 |
| Topiramate | Topiramate | 49 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | suppressed |
| Eszopiclone | Eszopiclone | 48 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 35 |
| Nitroglycerin | Nitroglycerin | 48 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 47 | suppressed |
| Metronidazole | Metronidazole | 47 | 36 |
| Rybelsus | Semaglutide | 47 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Scopolamine | Scopolamine | 46 | 18 |
| Acyclovir | Acyclovir | 45 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 45 | 45 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 45 | 36 |
| Azelastine Hcl | Azelastine Hcl | 44 | 20 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 44 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Telmisartan | Telmisartan | 42 | suppressed |
| Fentanyl | Fentanyl | 41 | suppressed |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 41 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 35 | 16 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 35 | 34 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 33 | 27 |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Dutasteride | Dutasteride | 32 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 18 |
| Naproxen | Naproxen | 32 | 16 |
| Premarin | Estrogens, Conjugated | 32 | suppressed |
| Haloperidol | Haloperidol | 31 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Anastrozole | Anastrozole | 30 | suppressed |
| Lubiprostone | Lubiprostone | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 15 |
| Fosinopril Sodium | Fosinopril Sodium | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 16 |
| Indomethacin | Indomethacin | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Prolia | Denosumab | 24 | 14 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 22 | 22 |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 13 |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Phenytoin | Phenytoin | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Entacapone | Entacapone | 18 | suppressed |
| Epinephrine | Epinephrine | 18 | 12 |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Mitigare | Colchicine | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,144.22 · 51 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, GEMTESA, JARDIANCE, Kerendia, Korlym, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error